These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 21125964)
21. Drug quality in South Africa: perceptions of key players involved in medicines distribution. Patel A; Norris P; Gauld R; Rades T Int J Health Care Qual Assur; 2009; 22(5):547-60. PubMed ID: 19725374 [TBL] [Abstract][Full Text] [Related]
22. Use of benchmarking in the development of biopharmaceutical products. Giffin M; McLeish S Biotechnol Annu Rev; 2003; 9():279-84. PubMed ID: 14650932 [TBL] [Abstract][Full Text] [Related]
23. The use of total quality principles to achieve regulatory compliance in research laboratories. Hynes MD Qual Assur; 1995 Mar; 4(1):34-40. PubMed ID: 8520863 [TBL] [Abstract][Full Text] [Related]
24. FDA 2011 process validation guidance: lifecycle compliance model. Campbell C PDA J Pharm Sci Technol; 2014; 68(2):185-91. PubMed ID: 24668605 [TBL] [Abstract][Full Text] [Related]
27. An introduction to benchmarking in healthcare. Benson HR Radiol Manage; 1994; 16(4):35-9. PubMed ID: 10139084 [TBL] [Abstract][Full Text] [Related]
28. [Benchmarking of radiological departments--starting point for successful process optimization]. Busch HP Rofo; 2010 Mar; 182(3):221-8. PubMed ID: 20143285 [TBL] [Abstract][Full Text] [Related]
29. Clinical quality assurance in the pharmaceutical industry. Donahue JJ Cancer Treat Rep; 1985 Oct; 69(10):1195-7. PubMed ID: 4042098 [No Abstract] [Full Text] [Related]
31. The regulation of biopharmaceuticals. Weisbroth N Qual Assur; 1993; 2(1-2):147-51. PubMed ID: 8156202 [No Abstract] [Full Text] [Related]
32. Two keys to deliver better care and measure quality: pod implementation & dashboards. Fracasso MR; Sanders B Physician Exec; 2012; 38(6):48-52, 54. PubMed ID: 23888652 [No Abstract] [Full Text] [Related]
33. Innovation and compliance are not diametrically opposed. Raab GK Qual Assur; 1994 Mar; 3(1):2-8. PubMed ID: 7804614 [No Abstract] [Full Text] [Related]
34. The FDA's reaction to corporate compliance audits. Shroff AP Food Drug Law J; 1996; 51(2):221-3. PubMed ID: 11820199 [No Abstract] [Full Text] [Related]
35. Experiences with GLP/GCP from the pharmaceutical industry's viewpoint. Legler UF Methods Find Exp Clin Pharmacol; 1993 May; 15(4):233-6. PubMed ID: 8361261 [TBL] [Abstract][Full Text] [Related]
36. The ReACH Collaborative--improving quality home care. Boyce PS; Pace KB; Lauder B; Solomon DA Caring; 2007 Aug; 26(8):44-51. PubMed ID: 17966307 [TBL] [Abstract][Full Text] [Related]
37. Industry perspectives on ICH guidelines. Rockhold FW Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111 [TBL] [Abstract][Full Text] [Related]
38. Meadville Medical Center's experience with the accelerating Best Care in Pennsylvania project: lessons learned and future directions. Dickey SJ; McNamara DE Am J Med Qual; 2008; 23(4):266-70. PubMed ID: 18658099 [TBL] [Abstract][Full Text] [Related]
39. The draft FDA guideline on non-inferiority clinical trials: a critical review from European pharmaceutical industry statisticians. Huitfeldt B; Hummel J; Pharm Stat; 2011; 10(5):414-9. PubMed ID: 21932294 [TBL] [Abstract][Full Text] [Related]
40. Above reproach: developing a comprehensive ethics and compliance program. Yuspeh A; Whalen K; Cecelic J; Clifton S; Cobb L; Eddy M; Fainter J; Packard J; Postal S; Steakley J; Waddey P Front Health Serv Manage; 1999; 16(2):3-38. PubMed ID: 10787844 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]